Higher rates of maternal vascular malperfusion (MVM) features* and decidual arteriopathy were observed in placentas of women who had coronavirus disease 2019 (COVID-19) during pregnancy, a study has shown.
There appears to be no benefit to taking dietary antioxidants, such as vitamins and carotenoids, in terms of reducing the risk of developing Parkinson’s disease (PD) in Asians, as shown in a Singapore study.
The next-generation automated insulin delivery (AID) system significantly improved daytime glycaemic control without increasing hypoglycaemia over the current 670G hybrid closed-loop system on the market in young patients with type 1 diabetes (T1D), according to the FLAIR* trial presented during the ADA 2020 Annual Meeting.
Pembrolizumab may extend progression-free survival (PFS) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) who are ineligible for or have relapsed following autologous stem-cell transplant (auto-SCT), according to the phase III KEYNOTE-204 trial.
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Singaporeans express feelings of fear, concern, and displeasure about the coronavirus disease 2019 (COVID-19) outbreak, and they were vocal about it on social media, according to a recent qualitative study.
Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.